血浆血管活性肽尾加压素II与动脉瘤性蛛网膜下腔出血后脑血管痉挛的关联:一个潜在治疗靶点
研究采用小鼠蛛网膜下腔出血模型探讨尾加压素II受体拮抗剂urantide对脑血管痉挛和神经功能结局的影响,并在神经外科重症监护室对17例蛛网膜下腔出血患者连续9天检测血浆尾加压素II水平,发现urantide可预防小鼠脑血管痉挛,而有症状性血管痉挛患者血浆尾加压素II中位水平高于无血管痉挛患者(77 pg/ml vs 37 pg/ml,p<0.05)。
要点
- 小鼠模型中urantide预防了脑血管痉挛及蛛网膜下腔出血相关精细运动协调障碍。
- 17例蛛网膜下腔出血患者血浆尾加压素II中位水平为43 pg/ml(IQR 14-80 pg/ml)。
- 有症状性血管痉挛患者9天内血浆尾加压素II中位水平高于无血管痉挛患者(77 pg/ml vs 37 pg/ml,p<0.05)。
核心结论
- 研究结果提示,在小鼠中urantide拮抗尾加压素受体可预防蛛网膜下腔出血后脑血管痉挛并改善神经功能结局。
- 在人类中,血浆尾加压素II升高与蛛网膜下腔出血后脑血管痉挛相关。
- 循环尾加压素II与蛛网膜下腔出血后脑血管痉挛之间的因果关系尚待确立,但根据本研究数据,尾加压素受体是蛛网膜下腔出血的潜在治疗靶点。
研究设计与样本
- 研究采用小鼠蛛网膜下腔出血模型研究尾加压素II及尾加压素受体拮抗剂/偏向性配体urantide对脑血管痉挛和神经功能结局的影响。
- 随后在神经外科重症监护室开展临床研究,对17例蛛网膜下腔出血并置入脑室外引流管的患者从住院第1天起连续9天每日检测血浆尾加压素II水平,并与健康志愿者血浆尾加压素II水平进行比较。
主要发现
- 小鼠模型中,urantide预防了脑血管痉挛以及蛛网膜下腔出血相关的精细运动协调障碍。
- 17例蛛网膜下腔出血患者血浆尾加压素II中位水平为43 pg/ml(IQR 14-80 pg/ml),从第0天至第8天每日中位血浆尾加压素II水平无显著变化。
- 有症状性血管痉挛患者蛛网膜下腔出血后前9天血浆尾加压素II中位水平高于无血管痉挛患者(77 pg/ml [IQR 33.5-111.5 pg/ml] vs 37 pg/ml [IQR 21-46 pg/ml],p < 0.05)。
- 在有症状性血管痉挛患者(中位66 pg/ml [IQR 30-110 pg/ml])与无血管痉挛患者(27 pg/ml [IQR 15-46 pg/ml],p < 0.001)之间,每日血浆尾加压素II水平存在显著差异。
- 有症状性血管痉挛患者与健康志愿者(44 pg/ml [IQR 27-51 pg/ml])之间、无血管痉挛患者与健康志愿者之间,血浆尾加压素II水平均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 循环尾加压素II与蛛网膜下腔出血后脑血管痉挛之间的因果关系尚待确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cerebral vasospasm (VS) is a severe complication of aneurysmal subarachnoid hemorrhage (SAH). Urotensin II (UII) is a potent vasoactive peptide activating the urotensin (UT) receptor, potentially involved in brain vascular pathologies. The authors hypothesized that UII/UT system antagonism with the UT receptor antagonist/biased ligand urantide may be associated with post-SAH VS. The objectives of this study were 2-fold: 1) to leverage an experimental mouse model of SAH with VS in order to study the effect of urotensinergic system antagonism on neurological outcome, and 2) to investigate the association between plasma UII level and symptomatic VS after SAH in human patients. METHODS: A mouse model of SAH was used to study the impacts of UII and the UT receptor antagonist/biased ligand urantide on VS and neurological outcome. Then a clinical study was conducted in the setting of a neurosurgical intensive care unit. Plasma UII levels were measured in SAH patients daily for 9 days, starting on the 1st day of hospitalization, and were compared with plasma UII levels in healthy volunteers. RESULTS: In the mouse model, urantide prevented VS as well as SAH-related fine motor coordination impairment. Seventeen patients with SAH and external ventricular drainage were included in the clinical study. The median plasma UII level was 43 pg/ml (IQR 14-80 pg/ml). There was no significant variation in the daily median plasma UII level (median value for the 17 patients) from day 0 to day 8. The median level of plasma UII during the 9 first days post-SAH was higher in patients with symptomatic VS than in patients without VS (77 pg/ml [IQR 33.5-111.5 pg/ml] vs 37 pg/ml [IQR 21-46 pg/ml], p < 0.05). Concerning daily measures of plasma UII levels in VS, non-VS patients, and healthy volunteers, we found a significant difference between SAH patients with VS (median 66 pg/ml [IQR 30-110 pg/ml]) and SAH patients without VS (27 pg/ml [IQR 15-46 pg/ml], p < 0.001) but no significant difference between VS patients and healthy volunteers (44 pg/ml [IQR 27-51 pg/ml]) or between non-VS patients and healthy volunteers. CONCLUSIONS: The results of this study suggest that UT receptor antagonism with urantide prevents VS and improves neurological outcome after SAH in mice and that an increase in plasma UII is associated with cerebral VS subsequent to SAH in humans. The causality link between circulating UII and VS after SAH remains to be established, but according to our data the UT receptor is a potential therapeutic target in SAH.
引用
- Clavier T, Mutel A, Desrues L, et al. Association between vasoactive peptide urotensin II in plasma and cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a potential therapeutic target. J Neurosurg. 2018. PMID: 30497195. doi:10.3171/2018.4.JNS172313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。